Engineered immune cells take on Drug-Resistant lung cancer

NCT ID NCT06097962

Recruiting now Disease control Sponsor: Base Therapeutics (Shanghai) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times

Summary

This early-stage study tests a new treatment called NK510 for people with advanced non-small cell lung cancer (NSCLC) that no longer responds to standard immunotherapy. NK510 are natural killer cells modified to block a protein called TIGIT, which may help them attack cancer more effectively. The study involves 12 participants and will evaluate safety and tumor response using two methods: intravenous infusion or direct injection into fluid around the lungs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Jinling hospital, affiliated to Medical school Nanjing University
RECRUITING

Nanjing, Jiangsu, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NSCLC